university of utah md phd

• About ECE & Utah
• Accreditation
• Chair Welcome
• Department Videos
• Department Login
• ECE Conference Room Calendars
• ECE Purchase Requisition
• Proposal Submission Resources
• Faculty Directory
• Administration Team
• Research Areas
• Awards and Recognition
• Funding Highlights
• Center for Engineering Innovation
• Utah Nanofab
• Undergraduate Research

Program Overview

• Transfer Students
• Resources for Students
• Departmental Scholarships
• PCE Scholarships
• Student Clubs
• Utah Asia Campus Summer Program
• CE Degree Requirements
• EE Degree Requirements
• Engineering Entrepreneurship Certificate
• Engineering Honors Program
• UU Course Catalog
• Objectives and Outcomes
• Senior Capstone
• Co-op / Internship
• Exception to Policy
• Major Status Application
• Permission Codes
• Special Studies Request Form
• Student Feedback
• Transfer Petition
• Teaching Assistants
• Apply to our Graduate Program
• Master’s via Remote Learning
• Proficiency Requirements
• Course Offerings & Tracks
• How to Transfer Credits
• Programs Overview
• BS/MS Combined
• Policies and Procedures
• Student Resources
• Grad SAC (Student Advisory Council)
• Permission Code Request
• TA Application
• ECE in the Media
• Faculty / Student News Submission
• News Archive
• Advisory Board
• Alumni Resources
• Donate Online
• Fundraising Priorities
• Update Your Information

ECE MD-PhD Program

The  MD-PhD Program at the University of Utah enables a select group of students to earn a 4-year MD degree through the School of Medicine and a Ph.D. in one of seven affiliated departments, including the Department of Electrical and Computer Engineering.  It is a rigorous program that provides an outstanding and fully-funded education for future physician-scientists, equipping them with fundamental clinical skills and experience conducting cutting-edge research that will prepare them for careers as biomedical researchers and clinician-scientists.

The ECE doctoral program prepares students to integrate scientific discovery and state-of-the-art technology into novel clinical applications and medical devices and is an excellent complement to the U’s top-tier MD Program. It emphasizes medical imaging systems, implantable medical devices, brain-computer interfaces, wearable technology, micro and nano-sized biomedical sensors, and artificial intelligence for various medical applications. ECE MD-PhD graduates join an elite group of leaders transforming healthcare through technological development, clinical implementation, and government regulation. 

Students of the Program complete two years of their MD, then apply to and complete a Ph.D. before returning to medical school to finish the final two years of their MD. Students are conferred at the time they finish their Ph.D. and again upon completion of their MD. A complete timeline can be found  here .

The MD-PhD program follows the same admissions criteria as the MD program but with a greater focus on research experience. Please refer to the,  Preparing for Medical School website  for details about premedical coursework and eligibility and the  Programs Admissions website  for information on admissions standards, policies, and procedures.

Initial MD-PhD program applications must be submitted to the American Medical College Application Services (AMCAS) and are only available to U.S. citizens or permanent U.S. residents. We encourage applications from qualified students nationwide, especially those with a background in engineering. 

Applicants must meet the following requirements when submitting their application: 

• Grade point averages above 3.0
• MCAT score of 500 or better (GRE scores are waived in place of MCAT scores)
• Submission of the MD-PhD Essay and a Significant Research Essay

Competitive applicants will have substantial experience in community and/or volunteer service, leadership, physician shadowing, patient exposure, and an academic career that includes a strong focus on research.

If admitted by the School of Medicine, students will have the opportunity to rotate through various research labs on campus to help identify a faculty mentor. Students can review the list of  ECE faculty to help identify potential research labs. After they’ve identified a lab, an application for admission to the ECE department Ph.D. program should be submitted through the Apply Yourself electronic application system by July 15th of the year they intend to begin their Ph.D.  See the ECE graduate student admissions website  for application details.

Course Requirements

In addition to the courses required by the Medical School, ECE MD-PhD students must complete at least 12 credit hours of ECE coursework, two credit hours of ECE graduate seminar, and at least 14 credit hours of Dissertation Research (ECE 7970). The Medical School curriculum serves as allied courses which make up the remaining 18 credit hours of coursework typically required by the ECE Ph.D. program. MD-PhD students are not required to TA or take any courses related to TAing. These students will gain mentorship and didactic teaching experience through the Medical School curriculum and supplemental activities outlined in the MD-PhD program.

Privacy Preference Center

Privacy preferences.

Neuroscience Program

Main navigation, neuroscience phd university of utah.

Want to apply?

For more information click the link below., university of utah indigenous land acknowledgement statement.

The University of Utah has both historical and contemporary relationships with Indigenous peoples. Given that the Salt Lake Valley has always been a gathering place for Indigenous peoples, we acknowledge that this land, which is named for the Ute Tribe, is the traditional and ancestral homelands of the Shoshone, Paiute, Goshute, and Ute Tribes and is a crossroad for Indigenous peoples. The University of Utah recognizes the enduring relationships between many Indigenous peoples and their traditional homelands. We are grateful for the territory upon which we gather today; we respect Utah’s Indigenous peoples, the original stewards of this land; and we value the sovereign relationships that exist between tribal governments, state governments, and the federal government. Today, approximately 60,000 American Indian and Alaska Native peoples live in Utah. As a state institution, the University of Utah is committed to serving Native communities throughout Utah in partnership with Native Nations and our Urban Indian communities through research, education, and community outreach activities.

The importance of setting ourlselves apart

Is the normal for us..

The primary goal of the Neuroscience Program at Utah is to develop well-rounded scientists who are passionate about science and will become the next generation of leaders in our society. 

The Neuroscience PhD Program at the University of Utah offers rigorous training through a combination of coursework, research training, mentoring, and professional development. More than 80 program faculty from 26 participating departments provide broad expertise from molecular and cellular neuroscience, to systems and cognitive neuroscience. 

Students receive hands-on training and mentorship within a world-class research environment, collegial and collaborative mentorship and a vibrant research community. They have the unique opportunity to develop professionally through a variety of student leadership roles, such as organizing the Annual Snowbird Neuroscience Symposium and Neuroscience Program Speaker Series.

Send your questions and inquiries about the Neuroscience PhD Program to our Program Manager at  [email protected]  

Application

Core Curriculum

Areas of Research

Program Philosophy

Program Outcomes

In the NeuroNews... NEURONEWSLETTER

BREO has Been Announced

Recent Awards

• Alicia Walker : NSF GRFP Honorable Mention
• Kaelan Sullivan : NIH F99/F00 D-SPAN
• Fei Chang : Utah Graduate Research Fellowship
• Qwynn Landfield : CTSI STARS T32 Award

Neuro SWAG is Arriving Soon

We've succefully have ran our first Neuroscience store! The sale lasted for the month of May. If you missed out don't worry we will have the sale run again this fall with new upgrades.

And don't forget to watch your email for when your package arrives to the office.  

Spencer Fox Eccles School of Medicine

School of medicine, md students, graduate medical education, student tools.

Spencer Fox Eccles School of Medicine combines excellence in teaching, research, and clinical expertise to train tomorrow's physicians for the rapidly changing world of medicine. With over 1,000 physicians and researchers, and 23 science departments, we are able to offer: 

• physician assistant training
• residencies
• fellowship specialty training
• degrees in public health
• degrees in medical laboratory science

We are widely recognized for  interdisciplinary research  in the genetics of disease, cancer, biomedical informatics, infectious diseases, and other areas of leading-edge medicine. 

Esta Es Mi Clínica

Stories from a student-led clinic

The greatest lesson medical students learn volunteering in a Midvale low-income clinic is compassion.

Departments

Latest News

Dr. Peng Zhang, PhD, Appointed to Research Track

Peng Zhang, PhD, has recently been appointed to Research Assistant Professor in the Department of Oncological Sciences.

Lab Coat Ceremony Celebration!

Celebrating students who passed their preliminary exam with the hand out of personalized lab coats. Congratulations recipients, you deserve it!

The GME Office welcomes Danika and Julia!

Pcmac accomplishments, 2024 uuh gme main residency match data.

Department of Emergency Medicine Spring 2024 Newsletter

Videos and other stories.

Match Day 2024

Student-Led Clinics

Longitudinal Integrated Clerkships

Why Student-Led Clinics are Good for Everyone

MD students and Ultrasound

Upcoming events, rheumatology conference.

8:00am - 8:45am   "Journal Club - SLE" presented by Dr. Rebecca Overbury, 8:45am - 9:30am...

DOIM Research Seminar Series

Department of Internal Medicine Research Seminar Series - to foster collaboration across divisions and beyond ...

2024 ASCENT Research Training Program in Sexual and Reproductive Health Rights and Justice

The ASCENT Research Training Program in SRHRJ is offering a 10-week summer intensive training program for a ...

Nephrology Clinical Conference

Topic: QIP, Presenter: Dr. Gurbir Sehmbey CME Eligible?: Yes Event Contact Name:&...

John Carey Foundation Series - Fellows & New Faculty

This CME series provides junior faculty and fellows with a common core curriculum in clinical excellence and ...

Mission Statement

The University of Utah Spencer Fox Eccles School of Medicine serves all people and communities of Utah and the Intermountain West by intentionally supporting and improving individual and community health outcomes and quality of life. This is achieved through excellence in equitable patient care, education, and research by:

• Purposefully educating scientists and health care professionals to ensure compassionate, equitable, patient-centered care to all, prioritizing communities of greatest need.
• Serving rural and underserved communities by prioritizing and acting to address social determinants of health to eliminate structures and practices that lead to health disparities among all people.
• Engaging in scholarly research to advance knowledge, innovation, well-being, and health equity for all people.
• Fostering a culture of belonging, anti-racism, and anti-discrimination through strategic recruitment, retention, and recognition of efforts among students, trainees, staff, faculty, and community partners.

This School of Medicine Alumni Association Fund is used to support medical student programming, student scholarships, and alumni outreach. It provided start-up funding for the Student Emergency Fund and the Wellness Program. It also funds special requests from the Dean of the School of Medicine, finances speakers for CME and other training, and helps cover housing costs for the Rural Utah Underserved Training Experience for students doing rotations in rural communities around the state.

Brian J. Mickey, MD, PhD

University of utah profiles.

• Faculty Affiliate , Neuroscience Program
• Adjunct Associate Professor , Biomedical Engineering
• Adjunct Associate Professor , Department Of Anesthesiology
• Professor (Clinical) , Psychiatry

Contact Information

Main office, mailing address.

Research Summary

• Practice History
• Teaching experience
• Research Statement
• Research Keywords
• Selected publications
• Honors & Awards
• Affiliations
• In the Media

Neuroscience of depression and related illnesses. https://medicine.utah.edu/psychiatry/research/labs/mickey-lab/

• BS/BS, Physics/Biology, University of Washington, Seattle
• MD/PhD, Medicine/Neuroscience, University of Michigan, Ann Arbor
• Residency/Fellowship, Psychiatry, Molecular & Behavioral Neuroscience Institute, University of Michigan
• Neurobiology of mood disorders
• Neural mechanisms of antidepressant agents
• Brain stimulation therapies

The Graduate School

University information technology (uit), main navigation.

• Events & Deadlines
• Degree Programs & Contacts

Building a Community of Scholars and Leaders

The Graduate School links you to resources that support success—from financial support and health & wellness resources, to themed workshops, travel funding, and much more.

students enrolled in graduate programs

graduate degrees offered by the U

million in research funding FY 2023

postdoctoral fellows and research associates

Graduate Admissions at the U Meet The Grad School

Announcements

view all announcements

Dissertation & Thesis Summer Writing Day

Join your fellow graduate students in this self-paced writing event and make a serious dent in your thesis or dissertation.

Congratulations Graduating Graduate Students!

Congratulations to all of our graduating students! Thank you for all that you’ve done for the U. Best wishes as you begin a new stage in your education and career

Stay Up To Date With All Things Graduate School

Follow us on Instagram to stay up-to-date on resources, events, scholarship opportunities and more all offered to U of U graduate students!

Grammarly Premium is available to University of Utah Graduate Students!

Graduate students are encouraged to use Grammarly throughout their graduate research career and to assist with writing their manuscripts.

Resource Quick Links 

Thesis & dissertation, degree requirements, responsible conduct of research, tuition benefit program, fellowships, scholarships & awards, travel assistance, mental wellness, health insurance, campus & community resources, professional development, graduate policies.

See all resources

Creating a Campus Climate that Welcomes All

We are committed to inclusiveness of students and professionals with diverse backgrounds and perspectives, to create a better academic environment for all.

Graduate School Diversity Office

International Student Info

We recognize and honor that the university is located on the traditional and ancestral homelands of the Shoshone, Paiute, Goshute and Ute tribes. Read the full Indigenous Land Acknowledgement .

FOR POSTDOCS

FOR FACULTY & STAFF

 FOR Directors of Graduate Studies

Events & Deadlines

View All Events

Wednesday 8:30am - 4:30pm

Dissertation & Thesis Summer Writing Day

Marriott Library - J. Willard (M LIB)

Thursday 12pm - 1pm

Immigration Options for Postdoctoral Scholars

Language & Communication Bldg (LNCO)

Friday  

Summer 2024 First Half Last Day to Reverse CR/NC Option

Wednesday  

Holiday: Juneteenth

Thursday  

Summer 2024 First Half Classes End

Summer 2024 full-term last day to withdraw from classes, connect with us, icon   instagram, icon linkedin.

Connect with your colleagues and strengthen your professional network.

Follow us on LinkedIn

Support the Grad School

When you give to the Grad School you assist us in our mission to serve students, postdoctoral fellows, staff and faculty by

icon offering financial assistance icon supporting innovative academic opportunities icon providing professional development

Give to the Grad School

Voices of U of U Health

University of Utah Health

• U Health Plans

Preparing Tomorrow’s Physician-Scientists

In the early ‘90s, physician-scientists were an endangered species. Really. People with both a medical degree and a PhD were scarce, and that was a problem. Many MD-PhD programs around the country were founded in response to the shortage.

The University of Utah School of Medicine created its MD-PhD program in 1993 as a response. It started very small, averaging about two students a year. It has grown ever since. We now select about eight stellar students annually.

Dual Degrees Are Hard, But They Matter

Earning an MD is a huge accomplishment by itself. Imagine what it’s like to work toward an MD and PhD simultaneously. It typically takes eight years to finish. Students start with two pre-clinical years of medical school training. They then spend the next four years completing the PhD before returning to med school for two more years of clinical work.

John Sanchez is one of our students currently in his last year of the program at the U. He has benefitted greatly from the integrated clinical and research training offered by the dedicated faculty here.

“MD-PhD training has provided me with a strong foundation in clinical and scientific rigor,” Sanchez said. “By working with physician-scientist mentors, I’ve learned how these two skills can be effectively combined for the best outcomes. Between the hands-on clinical curriculum and diverse clinical exposure, I feel well prepared to move on to my internship.”

MSTP Funding is a Boon

To date, the U has been able to give full scholarships to all of its extraordinary MD-PhD students. This includes full tuition waivers and a fellowship equivalent to the graduate student stipend—$29,130 in 2020-2021. This allows graduates of the program to make career choices without external financial influence.

We’ve historically had a strong program, but every program wants to get better. So, after almost 30 years in existence, we are applying for a grant from the National Institutes of Health (NIH) for Medical Science Training Program (MSTP) funding.

It is exactly the step up that we need. The funds would help us take the quality of our program to the next level and build a cadre of MD/PhD students to serve as mentors for other campus medical and graduate students with whom they regularly interact.

MSTP status would recognize the outstanding efforts of our trainees and faculty to improve our integrated program. It would also alert potential applicants that Utah is worthy of their serious consideration as one of the premier physician-scientist training environments in the U.S.

Growing and Diversifying 

In just the last five years, the number of students applying to our MD-PhD program has tripled, even without MSTP funds. We are also proud to have matriculated more diverse students in the last two to three years than in the previous 25 years combined. Our continuing partnership with the Diversity Outreach Program will strengthen our efforts to diversify our student base.

Staying Tight

One unique feature of our MD-PhD program is the high level of support among students. Amanda Truong is another of our seniors. She remembers how student mentors helped her prepare for her PhD exams, write grants, and transition back into medical school.

“Our tight-knit group fosters scientific excellence, collaboration, mentorship, and friendship,” Truong said. “The main advantage of the MD-PhD program is that we have a consistent support system from year one to year eight. We are so much stronger together than we can be individually, and I am grateful to be a part of this thriving collective effort.”

Future of Medical Science

Students like Sanchez and Truong really embody the goal of any MD-PhD program. We train physician-scientists to integrate scientific discovery into clinical practice; become leaders that contribute to all aspects of service in academic medicine, industry, and government; and serve as mentors and role models for future physician-scientists.

And that’s exactly what they will do and who they have become.

Michael Kay, MD-PhD

Michael Kay is a Professor in Biochemistry and H.A. and Edna Benning Presidential Chair in the School of Medicine at the University of Utah. Kay is also director of the MD-PhD Program and Chemical Biology T32 training grant. Before coming to Utah in 2001, he trained with Harold Scheraga at Cornell University (BA in Biology and Chemistry), Robert Baldwin at Stanford University (MSTP fellow in Biochemistry), and Peter Kim at MIT (Damon Runyon Postdoctoral Fellow). His lab employs mirror-image biology for the development of antiviral and antibacterial D-peptides, as well as for applications in synthetic biology.

DON'T MISS OUT. GOOD NOTES delivers to your inbox.

School Profile: University of Utah School of Medicine MD/PhD Program

Happy Tuesday! I hope everyone is doing well and enjoying the Fall weather. 

Today, we are excited to interview an accomplished UMD alum: Ashley Zachery-Savella. While at UMD, Ashley was part of the Gemstone Honors Program and graduated with a dual degree in Biochemistry and Neurobiology. She is currently in the second year of her neuroscience PhD, working in the Karen Wilcox Lab. She attends University of Utah School of Medicine (colloquially known as the U) as part of the MD-PhD program with a specific interest in epilepsy research. As a member of her school’s admissions committee, Ashley is here to share the ins and outs of her program. 

Why MD-PhD (not MD or PhD)?

Ashley wanted to do research going into college; working in a lab and doing her thesis within the Gemstone Honors Program reaffirmed her passions for a PhD. She switched to the MD-PhD pathway halfway through college- explaining that she wanted to make a difference not only long-term, through research and investigation, but also short-term through the direct medical treatment of patients. She is especially drawn to translational research , as it provides an avenue for research beyond just patient charts and basic science work; an MD-PhD was the perfect mix of both! 

“I ASK DIFFERENT QUESTIONS...I APPROACH PROBLEMS DIFFERENTLY BECAUSE OF THIS TRAINING AND I THINK THAT’S SOMETHING WE REALLY NEED IN THE FIELD.”

Ashley believes her MD-PhD training, in particular, allows her to fill a gap that currently exists in research. When reading and analyzing journal articles, her PhD classmates may choose to critique, for example, the animal sample size of an experiment- but her concern is how transferable these results may be to human patients. “Did they look at sex differences? Because there’s going to be different drug effects on hormones when you apply these to patients and not just rats…or are the drug’s side effects typically seen in humans being addressed in these animal trials?” These are the sorts of questions clinicians would ask due to their training, and this analytical lens toward research is what excites Ashley about an MD-PhD. 

Program Structure: 

Similar to other MD-PhD programs, the U is 2 years medicine, 4-5 years research, and then a final 2 years of medicine. What’s especially enticing about her school is that the MD-PhD is a less stringent program compared to the MD when it comes to GPA/MCAT cut-offs. Admissions still considers applicants who are a little below the cutoff if they have interesting essays or outstanding extracurriculars. Additionally, unlike the MD program, the MD-PhD program is not as limited by the number of in-state applicants, so there is a fairly high representation of out-of-state students at the U.  

According to Ashley, the University of Utah is especially strong in their research pertaining to genetics and cancer with the Huntsman Cancer Institute . The University also has a unique interdepartmental approach to their neuroscience program! So as a PhD neuroscience student, Ashley has the ability to work in a pharmacology lab with a colleague who is a bioengineering PhD student. This sort of interdisciplinary approach is great for those who are interested in combining their various academic passions. What makes the program’s neuroscience program even more robust is the fact that University of Utah is well funded with the Epilepsy Drug Development Contract from the U.S. government for the past 40 years!  

“The match rate for our MD-PhD program is excellent with most people here getting their first choice, including the Ivy’s.”

At the U, there is a program called CMC where students are assigned to a clinical mentor that remains with them throughout their four years of medical school and clinical skills classes. In addition, students have access to work in some of the best hospitals, all within walking distance of each other; these institutions include the Moran Eye Center , Intermountain Primary Children’s Hospital , and the Huntsman Cancer Institute . There is also a brand new women’s hospital as well as the new Craig H. Neilsen Rehabilitation Hospital . Students also have access to the VA and all the clinics downtown. In fact, most students volunteer with the homeless population at clinics and also act as Spanish translators. As you can see, there are a lot of opportunities to work as a student doctor in varying settings thanks to the school’s malpractice insurance. What’s also amazing is that students get to observe a variety of cases in the hospital that you typically wouldn’t see in the city- like medical injuries that come from farm machinery. 

Academics: 

In terms of academics, the first two years are pass/fail, and midterm tests are not for a grade (only the final). Students will take midterm tests to monitor their progress, but the final is what counts for the total of their final grade. Third and fourth clinical years are graded based on a pass/high pass/honors pass system. There is also the Alpha Omega Alpha honor society ranking system in which grades count, but Ashley emphasizes that when it comes to studying, the program is extremely collaborative. Students also have the opportunity to pursue the Pathways Program : graduate-level classes that count on a 4.0 scale where students can receive a certificate at the end. Ashley is part of the Personalized Medicine pathway which trains students in innovative medical treatment planning that accounts for individual differences in people’s genes, environments, and lifestyles. 

Life at the U: 

It’s very affordable! The stipend goes pretty far, as the cost of living is less. Ashley is paying less living in a house with pets (and without roommates) than she did living in a 2 bed/2 bath in Silver Spring, MD (with a roommate). 

“There’s great public transport (not as extensive as DC metro but doesn't catch on fire as often haha), and most of the buildings are new (they're even about to build an even NEWER medical school). Most buildings around here also have really nice views of the mountains. My lab’s building has floor to ceiling windows all the way around with lots of natural sunlight which was a nice step up from my old undergrad chem labs in the basement! We're in a big city with shopping centers, bars, and restaurants but also 30 minutes away from mountain trails, olympic parks, and the ski resorts. There's even foothill trails right behind the medical school. I used to commute on 495, so I definitely asked about traffic when I interviewed at places. Again, not the end of the world if places don't have that kind of stuff, but I know I appreciate my short commute, pretty environment, and nice lecture halls pretty much every time I use them.”

What is the program looking for? 

Ah yes, now that we have learned about all of the amazing things at the U, here are some specifics Ashley mentioned the admissions committee is looking for: 

Applicants who have a deep understanding of the commitment it takes to pursue an MD/PhD (time, effort, personal sacrifice, ect.) and the need for MD/PhDs. It isn’t enough to just enjoy shadowing and benchwork; applicants should be able to display a keen understanding of the holes this role would fill in the field. 

DIFFERENTIATE yourself-- this could be where your letters of recommendation and  essays can help you stand out. Letters of recommendation that simply say “they were the top X of the students I’ve worked with” do little in comparison to letters that specifically mention how you contributed to research; this is because each person has a different definition of excellence, and qualitative descriptions help bridge the gap of knowledge between letter writer and reader. As for essays, Ashley recommends taking every opportunity to write a secondary because it allows the admissions committee to learn more about you and shows you are committed to their program and not just “copying and pasting” responses from other applications. 

For the cultural competency essay question, it’s important for one to be in touch with the fact “I had a great upbringing and here’s how I want to help others because I had so many opportunities...” Admissions wants to see you will be able to empathize with those different from you when interacting with patients. 

Hopefully, this gave folks insight on the University of Utah School of Medicine MD-PhD Program and encouraged you all to add it to your school list. Let us know any success stories in the comments if you choose to apply and/or attend. If you liked this post, look out for next week as Ashley details what you should be asking programs when you apply. Until next time, stay healthy! 

With care, 

**Tip from Ashley: Ask programs about how successful students are at getting funding/grants! At the U, students are required to apply for F30 grants and, impressively, about 66% of students get their F30s. Even more students are fully funded through things like training or departmental grants. If you get an F30, the program also gives students a raise in their stipend. If you are going to be an MD-PhD, Ashley says you want to make sure you are well prepared for applying for fellowships and grants in the future, so looking for grant-writing workshop opportunities will only prepare you for success. Ashley believes one of the reasons why students at Utah do so well is because previous F30 winners teach a class for those getting ready to apply, and they tell them what the reviewers are looking for and give good examples to follow.

You can even get this exposure now as an undergraduate researcher! One of our blog editors learned from Dr. Millner that undergrads and graduate students should reach out to major research professors and ask them how they get funds outside of what UMD provides. Students can even ask these seasoned professors if there is an opportunity to get involved in any part of their team’s grant writing process to get some hands-on experience and learn about how a team approach to the process can work. 

Stay In Touch

Alumni, please share your career updates and volunteer to be featured on an upcoming blog post. We love hearing from you!

University of Utah Hospital

General questions.

• Billing & Insurance

Howard Colman, MD, PhD

Clinical locations, huntsman cancer institute - cancer hospital south.

• Clinical Information
• Academic Information
• News & Podcasts

Howard Colman, MD, PhD, has multiple clinical interests including the treatment of primary and metastatic brain tumors, and the diagnosis and management of neurologic complications of cancer. His clinical research is focused on the development and testing of new therapies for brain tumors. His laboratory interests include the identification of molecular markers of prognosis and treatment response in brain tumors and the role of tumors stem cells in the development and treatment resistance of brain tumors. He is a Jon M. Huntsman Presidential Professor in the Department of Neurosurgery, a member of the multidisciplinary Brain Tumor Research Team, and is Leader of the Center for Neurologic Cancers at Huntsman Cancer Institute (HCI) at the University of Utah. He is also an HCI investigator and a member of the Experimental Therapeutics program.

Specialties

• Brain Tumors
• Spinal Cord Tumors
• General Neurology
• Neurosurgery
• Neuro-Oncology

Board Certification

Patient rating.

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Tremendous understanding of general knowledge surrounding overall issues of my medical situation, and rare ability to apply that understanding to my specific situation--and then to communicate clearly and work together toward a treatment plan. Can recommend without hesitation.

In addition to accomplishing the main purposes of our visit he diagnosed a problem I was having in my mouth that was causing me great difficulty and prescribed medicine for it.

Dr. Colman brought back my hope in this situation. He gave me positive encouragement in my situation. He gave me hope for the future and what it could hold for me. After almost 3 weeks in the hospital and feeling that there was very little hope left for me, his approach to my future care and continuing radiation he gave me my hope back.

First of all, after receiving the medical care from a replacement doctor, they left me on the waiting room for over an hour¿Not very happy.

Amazing doctor!

Terrific doctor. Brilliant and clear communicator.

Dr Colman has kept me informed all along the way as new things come up and new treatments are required.

Excellent physician, knowledgable and prompt.

Very knowledgeable and helpful.

Dr. Colman is always very professional and very friendly. I trust him to make proper decisions on my behalf. I feel like I am very lucky to have him as my doctor.

I know Dr Colman has a lot of patients to see, but waiting 1 to 2 hours just for the PA is disappointing.

Dr Colman is always very attentive to my concerns and questions. And he goes into detail with me during my appointments.

Dr Colman is amazing at explaining things to us and always lets us know our options. He is brilliant and his team is awesome too.

Treated me very well!!

Terrific, thoughtful guidance in thinking through complex healthcare decisions.

Dr. Colman is very knowledgeable. He took the time to explain what was going on and made sure all of our questions were answered.

Dr Coleman and his PA Sean are amazing. We feel so lucky to have them on our side through this difficult time. They listen, they recommend, and they give reason to their recommendations.

He explained and showed me the MRI and answered my questions.

Dr Colman is very caring and very professional, we think hes a very Awesome doctor!

blessed beyond expression to have someone not only at the top of his profession, but patient, kind and articulate.

I love Dr. Colman, hes a straight shooter with a dry seen of humor and has always let me know of all my options as things have come up.

Huntsman was great, getting my orders to intermountain Health took time I had call over 5 days to make the appointment for the mri

Dr. Colman is wonderful! He always listens to my symptoms/concerns and is very personable.

I can't say enough about the effect Dr. Colman has had on my life. I trust his expertise and appreciate his thorough, analytical approach.

He and Sean are an amazing team and I trust him implicitly with my care.

He's professional and straightforward. He doesn't rush through the appointment and answers my husband's questions with patience.

Always honest and respectful Great Drs and team.

Dr Coleman is the best oncologist I've ever had. I would recommend him to anyone who needed help.

Lack of communication

They are very good

Very much appreciated reviewing MRI scan with doctor, and the advice regarding "type A" personalities and aging was golden -- both my husband and I benefited from that.Definitely felt like we were in good hands, and in the right hands.

I did not to have a timeline as to the progression of my cancer, but he gave me one despite this. However, my caregivers benefited from the knowledge.

Shawn is very knowledgeable and easy to speak to. He does a great job.

Overall very happy with the care and services we received.

It was a very quick appointment but those are the ones I prefer. Dr. Colman came in, showed me my images from before and after treatment, made sure I was still doing okay and that I didn't have questions and we went on our way. The quicker the appointment at this office the better in my opinion because that means things are going right.

Dr Colman and Dr McKean were very professional and thorough

Allowed my wife to participate via Face Time. That was nice.

Dr. Colman and Sean are who I would recommend to people locally for treatment of brain tumors.

Board Certification and Academic Information

Education history, selected publications, journal article.

• Peoples, A, Oswald L, Ose, J, Daniels B, Himbert C, Hathaway, C, Gigic B, Kirchhoff A, Lin T, Grossman D, Tward J, Varghese Jr T, Figueiredo J, Toriola A, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez, B, Salas K, Ashworth A, Matsen C, Christenson C, Ma D, Colman H , Hunt J, Jones K, Lee C, Larson M, Onega T, Akerley, W, Li C, Schneider M, Penedo F, Siegel E, Tworoger S, Ulrich C (). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. (Epub ahead of print) J Rural Health .
• McKean WB, Yang J, Boucher K, Shrieve DC, Suneja G, Salzman K, Jensen R, Colman H , Cohen AL (2024). D-TERMINED, a phase 1 trial in newly diagnosed high-grade glioma with temozolomide, radiation, and minocycline followed by adjuvant minocycline/temozolomide. Neurooncol Adv , 6 (1), vdae063. ( Read full article )
• Underhill HR, Karsy M, Davidson CJ, Hellwig S, Stevenson S, Goold EA, Vincenti S, Sellers DL, Dean C, Harrison BE, Bronner MP, Colman H , Jensen RL (2024). Subclonal Cancer Driver Mutations are Prevalent in the Unresected Peritumoral Edema of Adult Diffuse Gliomas. Cancer Res , 84 (7), 1149-1164. ( Read full article )
• Demetriou AN, Chow F, Craig DW, Webb MG, Ormond DR, Battiste J, Chakravarti A, Colman H , Villano JL, Schneider BP, Liu JKC, Churchman ML, Zada G (2024). Profiling the molecular and clinical landscape of glioblastoma utilizing the Oncology Research Information Exchange Network brain cancer database. Neurooncol Adv , 6 (1), vdae046. ( Read full article )
• Arnold LM, Hoshina Y, Lee H, Colman H , Mendez J (2024). Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors. J Neurooncol , 167 (1), 211-217. ( Read full article )
• Amann E, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman DTward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Branes CA, Matsen C, Ma DS, Colman H , Hunt JPJones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Ott o AKPenedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic . Journal of Behavioral Medicine , 47 (3), 405-421.
• Eljilany I, Saghand PG, Chen J, Ratan A, McCarter M, Carpten J, Colman H , Ikeguchi AP, Puzanov I, Arnold S, Churchman M, Hwu P, Conejo-Garcia J, Dalton WS, Weiner GJ, El Naqa IM, Tarhini AA (2023). The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors. Cancers (Basel) , 15 (20), 4913. ( Read full article )
• Rahman R, Trippa L, Lee EQ, Arrillaga-Romany I, Fell G, Touat M, McCluskey C, Wiley J, Gaffey S, Drappatz J, Welch MR, Galanis E, Ahluwalia MS, Colman H , Nabors LB, Hepel J, Elinzano H, Schiff D, Chukwueke UN, Beroukhim R, Nayak L, McFaline-Figueroa JR, Batchelor TT, Rinne ML, Kaley TJ, Lu-Emerson C, Mellinghoff IK, Bi WL, Arnaout O, Peruzzi PP, Haas-Kogan D, Tanguturi S, Cagney D, Aizer A, Doherty L, Lavallee M, Fisher-Longden B, Dowling S, Geduldig J, Watkinson F, Pisano W, Malinowski S, Ramkissoon S, Santagata S, Meredith DM, Chiocca EA, Reardon DA, Alexander BM, Ligon KL, Wen PY (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol , 41 (36), 5524-5535. ( Read full article )
• Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H , Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M (2023). Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med , 29 (10), 2402-2405. ( Read full article )
• Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H , Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, Lpez-Janeiro, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G (2023). Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med , 29 (6), 1370-1378. ( Read full article )
• Earl ER, Colman H , Mendez J, Jensen RL, Karsy M (2023). An evaluation of biobanking and therapeutic clinical trial representation among adult glioma patients from rural and urban Utah. Neurooncol Pract , 10 (5), 472-481. ( Read full article )
• Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H , Cohen AL, Ormond DR, Neil EC, Chakravarti A, Willmarth N, Balajonda BC, Menon J, Ma J, Bauer H, Nelson RS, Tan MS, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D (2023). Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study. Future Oncol , 19 (2), 173-188. ( Read full article )
• Wu Z, Rajan S, Chung HJ, Raffeld M, Panneer Selvam P, Schweizer L, Perry A, Samuel D, Giannini C, Ragunathan A, Frosch MP, Marshall MS, Bou DR, Donev K, Neill SG, Fernandes I, Resnick A, Rood B, Cummings TJ, Buckley AF, Szymanski L, Neto OLA, Zach L, Colman H , Cheshier S, Ziskin J, Tyagi M, Capper D, Abdullaev Z, Cimino PJ, Quezado M, Pratt D, Aldape K (2022). Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions. Acta Neuropathol , 144 (6), 1175-1178. ( Read full article )
• Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H , Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW (2022). Replicative Instability Drives Cancer Progression. Biomolecules , 12 (11). ( Read full article )
• Cimino PJ, Ketchum C, Turakulov R, Singh O, Abdullaev Z, Giannini C, Pytel P, Lopez GY, Colman H , Nasrallah MP, Santi M, Fernandes IL, Nirschl J, Dahiya S, Neill S, Solomon D, Perez E, Capper D, Mani H, Caccamo D, Ball M, Badruddoja M, Chkheidze R, Camelo-Piragua S, Fullmer J, Alexandrescu S, Yeaney G, Eberhart C, Martinez-Lage M, Chen J, Zach L, Kleinschmidt-DeMasters BK, Hefti M, Lopes MB, Nuechterlein N, Horbinski C, Rodriguez FJ, Quezado M, Pratt D, Aldape K (2022). Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1. Acta Neuropathol , 145 , 71-82. ( Read full article )
• Gelhard S, Maxwell A, Colman H , Cohen AL, Mendez JS (2022). Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis. J Neurooncol , 159 (2), 293-300. ( Read full article )
• de la Fuente MI, Colman H , Rosenthal M, Van Tine BA, Levacic D, Walbert T, Gan HK, Vieito M, Milhem MM, Lipford K, Forsyth S, Guichard SM, Mikhailov Y, Sedkov A, Brevard J, Kelly PF, Mohamed H, Monga V (2022). Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial. Neuro Oncol , 25 , 146-156. ( Read full article )
• Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H , Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control , 33 (7), 939-950. ( Read full article )
• Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H , Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Yung WKA, van den Bent M, Wen PY, Cloughesy TF (2022). Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors. Neuro Oncol , 24 , 1219-1229. ( Read full article )
• Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H , Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health , 38 (4), 886-899. ( Read full article )
• Brat DJ, Aldape K, Bridge JA, Canoll P, Colman H , Hameed MR, Harris BT, Hattab EM, Huse JT, Jenkins RB, Lopez-Terrada DH, McDonald WC, Rodriguez FJ, Souter LH, Colasacco C, Thomas NE, Yount MH, van den Bent MJ, Perry A (2022). Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas. Arch Pathol Lab Med , 146 (5), 547-574. ( Read full article )
• Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H , de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J (2021). Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neurooncol Adv , 4 (1), 1-10. ( Read full article )
• Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H , Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M (2021). Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res , 28 , 585-593. ( Read full article )
• Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H , Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D (2022). Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Support Care Cancer , 30 (2), 1365-1375. ( Read full article )
• Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H , Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M (2021). Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer , 9 (7). ( Read full article )
• Wang X, Haaland B, Hu-Lieskovan S, Colman H , Holmen SL (2021). First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Rep (Hoboken) , 4 (6), e1419. ( Read full article )
• Holowatyj AN, Viskochil R, Ose D, Tingey B, Haaland B, Wilson D, Larson M, Feltz S, Lewis MA, Colman H , Ulrich CM (2020). Diabetes, Body Fatness, and Insulin Prescription Among Adolescents and Young Adults with Cancer. J Adolesc Young Adult Oncol , 10 (2), 217-225. ( Read full article )
• Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H , Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh AH (2020). A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med , 13 (584). ( Read full article )
• Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H , van den Bent MJ, Wen PY, Alfred Yung WK, Cloughesy TF, Goldin JG (2020). Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro Oncol , 23 (2), 189-198. ( Read full article )
• Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H , McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA (2020). Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res , 27 (4), 1048-1057. ( Read full article )
• Colman H (2020). Adult Gliomas. Continuum (Minneap Minn) , 26 (6), 1452-1475. ( Read full article )
• Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H , Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR (2020). A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol , 22 (10), 1505-1515. ( Read full article )
• Werner CK, Nna UJ, Sun H, Wilder-Romans K, Dresser J, Kothari AU, Zhou W, Yao Y, Rao A, Stallard S, Koschmann C, Bor T, Debinski W, Hegedus AM, Morgan MA, Venneti S, Baskin-Bey E, Spratt DE, Colman H , Sarkaria JN, Chinnaiyan AM, Eisner JR, Speers C, Lawrence TS, Strowd RE, Wahl DR (2020). Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. Mol Cancer Ther , 19 (10), 2163-2174. ( Read full article )
• Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol , 148 (3), 577-585. ( Read full article )
• Brat DJ, Aldape K, Colman H , Figrarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M (2020). cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol , 139 (3), 603-608. ( Read full article )
• Smith-Cohn M, Davidson C, Colman H , Cohen AL (2019). Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases. CNS Oncol , 8 (4), CNS48. ( Read full article )
• Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H , Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY (2019). Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery , 85 (3), E607-E608. ( Read full article )
• Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H , Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL (2019). Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol , 37 (9), 741-750. ( Read full article )
• Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, OBrien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H , Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019). Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med , 25 (3), 477-486. ( Read full article )
• Hummel S, Kohlmann W, Kollmeyer TM, Jenkins R, Sonnen J, Palmer CA, Colman H , Abbott D, Cannon-Albright L, Cohen AL (2019). The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. BMC Cancer , 19 (1), 190. ( Read full article )
• Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Du D, Creighton CJ, Mills GB, Cancer Genome Atlas Research Network, Camargo F, Liang H (2018). Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. Cell Rep , 25 (5), 1304-1317.e5.
• Ippen FM, Colman H , van den Bent MJ, Brastianos PK (2018). Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet? Am Soc Clin Oncol Educ Book , 38 (38), 158-167. ( Read full article )
• Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H , Holmen SL (2018). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep , 23 (5), 1553-1564. ( Read full article )
• Frandsen J, Orton A, Jensen R, Colman H , Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg , 128 (4), 1133-1138. ( Read full article )
• Colman H (2017). Toward more informative biomarker-based clinical trials in glioblastoma. Neuro Oncol , 19 (7), 880-881. ( Read full article )
• Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen MC, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Nageswara Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognr L, Klekner A, Hortobgyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuon T, Schller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H , Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD (2016). Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Epub ahead of print]. J Clin Oncol , 34 (21), 2468-2477.
• Butowski N, Colman H , De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol , 18 (4), 557-64. ( Read full article )
• Karsy M, Guan J, Jensen R, Huang LE, Colman H (2016). The Impact of Hypoxia and Mesenchymal Transition on Glioblastoma Pathogenesis and Cancer Stem Cells Regulation. World Neurosurg , 88 , 222-236. ( Read full article )
• Ceccarelli M, et al TCGA Research Network, Colman H (2016). Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell , 146 (3), 550-563.
• Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H , Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S (2015). Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. J Neurosci , 35 (45), 15097-112. ( Read full article )
• Yuan S, Lu Y, Yang J, Chen G, Kim S, Feng L, Ogasawara M, Hammoudi N, Lu W, Zhang H, Liu J, Colman H , Lee JS, Li XN, Xu RH, Huang P, Wang F (2015). Metabolic activation of mitochondria in glioma stem cells promotes cancer development through a reactive oxygen species-mediated mechanism. Stem Cell Res Ther , 6 (1), 198. ( Read full article )
• Balasubramaniyan V, Vaillant B, Wang S, Gumin J, Butalid ME, Sai K, Mukheef F, Kim SH, Boddeke HW, Lang F, Aldape K, Sulman EP, Bhat KP, Colman H (2015). Aberrant mesenchymal differentiation of glioma stem-like cells: implications for therapeutic targeting. Oncotarget , 6 (31), 31007-17. ( Read full article )
• Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H , Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM (2015). Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol , 17 (8), 1051-63. ( Read full article )
• Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, Sulman E, Wang Q, Marini FC, Andreeff M, Colman H , Lang FF (2015). Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells , 33 (8), 2400-15. ( Read full article )
• Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock L, South ST, Abegglen LM, Schiffman JD, Colman H (2015). DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. Acta Neuropathol Commun , 3 , 34. ( Read full article )
• The Cancer Genome Atlas Network (2015). Comprehensive and Integrative Genomic Characterization of Diffuse Lower Grade Gliomas DOI: 10.1056/NEJMoa1402121 *Includes Colman, H. N Engl J Med , 372 (26), 2481-2498.
• Choi H, Gillespie DL, Berg S, Rice C, Couldwell S, Gu J, Colman H , Jensen RL, Huang LE (2015). Intermittent induction of HIF-1α produces lasting effects on malignant progression independent of its continued expression. PLoS One , 10 (4), e0125125. ( Read full article )
• Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H , Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, CERN Foundation (2014). Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol , 17 (3), 440-7. ( Read full article )
• Karsy M, Neil JA, Guan J, Mahan MA, Colman H , Jensen RL (2015). A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus , 38 (3), E4. ( Read full article )
• Chen R, Ravindra VM, Cohen AL, Jensen RL, Salzman KL, Prescot AP, Colman H (2015). Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. Neurosurg Focus , 38 (3), E2. ( Read full article )
• Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H , Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative (2015). Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol , 17 (2), 266-73. ( Read full article )
• Cohen AL, Colman H (2015). Glioma biology and molecular markers. Cancer Treat Res , 163 , 15-30. ( Read full article )
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H , Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med , 370 (8), 699-708. ( Read full article )
• Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H , Verhaak RG, Yung WK, Koul D (2014). A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells , 32 (1), 301-12. ( Read full article )
• Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H , Sulman EP, Aldape K (2013). Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell , 24 (3), 331-46. ( Read full article )
• Chen R, Cohen AL, Colman H (2016). Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. [Review]. Curr Treat Options Oncol , 17 (8), 42. ( Read full article )
• Karsy M, Guan J, Cohen A, Colman H , Jensen RL (2016). Medical Management of Meningiomas: Current Status, Failed Treatments, and Promising Horizons. [Review]. Neurosurg Clin N Am , 27 (2), 249-60. ( Read full article )

Case Report

• Sivakumar W, Oh N, Cutler A, Colman H , Couldwell WT (2015). Cranial and spinal leptomeningeal dissemination in esthesioneuroblastoma: Two reports of distant central nervous system metastasis and rationale for treatment. Surg Neurol Int , 6 (Suppl 25), S628-32. ( Read full article )
• Colman H (2019). A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. 21 (1), 6-7.
• Au TH, Willis C, Reblin M, Peters KB, Nghiemphu PL, Taylor JW, Colman H , Cohen AL, Ormond DR, Chakravarti A, Willmarth N, Menon J, Ma J, Bauer H, Watanabe AH, Ulrich CM, Singh P, Marshall A, Korytowsky B, Stenehjem D, Brixner D (2021). Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. Support Care Cancer ( 30 (2), pp. 1377-1378). Germany. ( Read full article )
• Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H , Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Res Sq . United States. ( Read full article )
• University of Texas M.D. Anderson Cancer Center, Colman H, Zhang L, Aldape K (2009). Multigene Assay to Predict Outcome in an Individual with Glioblastoma. U.S. Patent No. PCT/U808/55472. Washington, D.C.:U.S. Patent and Trademark Office.

News & Podcasts

Huntsman cancer institute news.

• Breakthrough in Glioblastoma Treatment with the Help of a Virus
• Clinical Trial Hopes to Shed New Light on Glioblastoma
• Howard Colman, MD, PhD, as Experimental Therapeutics Program Co-Leader

Dipayan Chaudhuri, MD, PhD

Director, CVRTI Metabolism, Assistant Professor of Internal Medicine, Adjunct Assistant Professor of Biochemistry

(801) 585-7676

[email protected] Chaudhuri Lab

Dr. Chaudhuri earned his medical and graduate degrees at the Johns Hopkins University School of Medicine. He then completed a residency in internal medicine at the University of California, San Francisco and subsequently a clinical fellowship in Cardiovascular Diseases at the Massachusetts General Hospital. Concurrently with his clinical fellowship, he completed a postdoctoral research fellowship at Massachusetts General Hospital and Boston Children’s Hospital. Dr. Chaudhuri joined the faculty of the Cardiovascular Division at the University of Utah in January 2016 as an Assistant Professor.  He is also an investigator at the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) on the Health Sciences Campus. His research focuses on changes in metabolism during heart failure. Dr. Chaudhuri is an attending physician on the Cardiovascular Medical Unit and on the Cardiology Consult Service at the University of Utah Hospital, with a clinical specialty in General Cardiology.

You seem to be using an unsupported browser

To get the best user experience please use a supported browser. Here are a few we recommend:

• MD/PhD Program in Medicine

Salt Lake City, UT

MD/PhD Program in Medicine / MD/PhD Program in Medicine is located in Salt Lake City, UT, in an urban setting.

Degrees & Awards

Degrees offered, degrees awarded, earning your degree, degree requirements, acceptance rate, application deadlines, entrance requirements, tuition & fees, financial support, student body, race/ethnicity, location & contact.

• Grad Schools
• Search Results
• University of Utah
• School of Medicine